RSV Vaccine for Adults: New Recommendations & Who Should Get It

For the first time, a broad swathe of American adults now have a recommended vaccine against respiratory syncytial virus, or RSV. The Centers for Disease Control and Prevention (CDC) updated its guidance in February 2026, recommending a single dose for all adults aged 75 and older, and for those between 50 and 74 who are at increased risk of severe illness. This marks a significant shift in preventative healthcare, addressing a virus that, while often mild, can be dangerous for vulnerable populations.

Who Benefits from the Fresh RSV Vaccine Recommendations?

RSV is a common respiratory virus that typically causes cold-like symptoms. However, it can lead to more serious complications, including bronchiolitis and pneumonia, particularly in infants and older adults. The new recommendations aim to protect those most susceptible to severe outcomes. Specifically, the CDC advises vaccination for all adults 75 years and older, regardless of their underlying health conditions.

For adults aged 50 to 74, the recommendation is more targeted. Vaccination is advised for individuals with certain chronic medical conditions that increase the risk of severe RSV disease. These conditions include chronic cardiovascular disease (like heart failure or coronary artery disease), chronic lung disease (such as COPD or asthma), end-stage renal disease requiring dialysis, diabetes complicated by kidney disease or nerve damage, and neurological or neuromuscular conditions that weaken airway clearance.

It’s important to note that the RSV vaccine is not currently recommended as an annual shot. Individuals who have already received one dose are considered fully vaccinated at this time, according to the CDC.

Understanding the Available RSV Vaccines

Currently, three RSV vaccines are licensed for use in adults aged 50 and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo. The CDC states there is no preference for which vaccine an adult should receive. This provides flexibility for healthcare providers and patients, allowing them to choose based on availability and individual circumstances.

Timing and Co-administration Considerations

While eligible adults can receive the RSV vaccine at any time, the optimal timing is generally considered to be in late summer and early fall, before RSV typically begins to circulate widely in the community. This allows the body to develop immunity before the peak season.

The CDC also acknowledges that co-administering the RSV vaccine with other adult vaccines – such as the flu or COVID-19 vaccine – may increase the frequency of common side effects like pain at the injection site, fever, headache, and muscle aches. Healthcare providers should consider this when making vaccination decisions and discuss potential side effects with patients.

The Evidence Behind the Recommendations

The recommendations are based on clinical trial data demonstrating the efficacy of the RSV vaccines in preventing severe illness, and hospitalization. For example, trials of Abrysvo, Arexvy, and mResvia showed significant protection against RSV-related lower respiratory tract disease in older adults. However, it’s crucial to understand the limitations of these trials.

Most trials focused on specific populations and age groups. While the vaccines demonstrated strong efficacy in these groups, the level of protection may vary in different populations or among individuals with multiple comorbidities. The long-term durability of protection remains under investigation. Ongoing surveillance and monitoring will be essential to assess the real-world effectiveness of the vaccines and to identify any potential waning of immunity over time.

RSV Vaccination During Pregnancy: A Separate Recommendation

Alongside the adult recommendations, the CDC and the American College of Obstetricians and Gynecologists (ACOG) recommend RSV vaccination for pregnant patients during weeks 32-36 of pregnancy. Here’s a different approach aimed at protecting infants in their first few months of life, before they are eligible for direct vaccination. The maternal vaccine stimulates the production of antibodies that are passed to the baby, providing passive immunity. Nirsevimab and clesrovimab are also recommended for infants under 8 months whose parent did not receive the RSV vaccine during pregnancy.

What Does This Mean for Public Health Surveillance?

The introduction of RSV vaccines necessitates enhanced public health surveillance to monitor vaccine effectiveness, identify any emerging safety concerns, and track the overall impact on RSV disease burden. The CDC and other public health agencies will likely continue to monitor RSV cases, hospitalizations, and deaths, paying close attention to trends in vaccinated and unvaccinated populations. This data will be crucial for informing future vaccination recommendations and strategies.

Hospital Surveillance Signals

Increased hospital surveillance will be key to understanding how the vaccines are performing in real-world settings. Monitoring rates of RSV-related hospitalizations among different age groups and risk categories will provide valuable insights into vaccine effectiveness and the need for potential booster doses or adjustments to vaccination strategies.

Looking Ahead: Ongoing Research and Guidance Updates

The RSV vaccination landscape is evolving rapidly. Researchers are continuing to investigate the long-term durability of protection offered by the current vaccines, as well as the potential need for booster doses. Further studies are also underway to assess the effectiveness of the vaccines in diverse populations and among individuals with complex medical conditions.

The CDC and other advisory bodies will regularly review the latest data and update their recommendations accordingly. We see essential for healthcare providers and the public to stay informed about these updates to ensure that vaccination strategies remain aligned with the best available evidence. For the most current information, consult the CDC website and discuss any questions or concerns with a qualified healthcare professional.